|DNA-repair defects and olaparib in metastatic prostate cancer|
J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ...
New England Journal of Medicine 373 (18), 1697-1708, 2015
|Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage …|
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
The Lancet 387 (10024), 1163-1177, 2016
|Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer|
K Fizazi, NP Tran, L Fein, N Matsubara, A Rodriguez-Antolin, ...
New England Journal of Medicine 377 (4), 352-360, 2017
|Abiraterone for prostate cancer not previously treated with hormone therapy|
ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ...
New England Journal of Medicine 377 (4), 338-351, 2017
|The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population|
RO Illing, JE Kennedy, F Wu, GR Ter Haar, AS Protheroe, PJ Friend, ...
British journal of cancer 93 (8), 890, 2005
|The type 1 insulin-like growth factor receptor pathway|
MM Chitnis, JSP Yuen, AS Protheroe, M Pollak, VM Macaulay
Clinical cancer research 14 (20), 6364-6370, 2008
|Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial|
AJ Armstrong, S Halabi, T Eisen, S Broderick, WM Stadler, RJ Jones, ...
The Lancet Oncology 17 (3), 378-388, 2016
|Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance|
C Kollmannsberger, T Tandstad, PL Bedard, G Cohn-Cedermark, ...
Journal of Clinical Oncology 33 (1), 51-57, 2014
|Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells|
T Aleksic, MM Chitnis, OV Perestenko, S Gao, PH Thomas, GD Turner, ...
Cancer research 70 (16), 6412-6419, 2010
|Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase …|
K Fizazi, C Massard, P Bono, R Jones, V Kataja, N James, JA Garcia, ...
The lancet oncology 15 (9), 975-985, 2014
|Reo-10: a phase 1 study of intravenous reovirus and docetaxel in patients with advanced cancer|
C Comins, J Spicer, A Protheroe, V Roulstone, K Twigger, CL White, ...
Clinical Cancer Research, clincanres. 1233.2010, 2010
|Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial|
ND James, MR Sydes, MD Mason, NW Clarke, J Anderson, DP Dearnaley, ...
The lancet oncology 13 (5), 549-558, 2012
|Extracorporeal high intensity focused ultrasound for renal tumours: a 3‐year follow‐up|
RW Ritchie, T Leslie, R Phillips, F Wu, R Illing, G Ter Haar, A Protheroe, ...
BJU international 106 (7), 1004-1009, 2010
|Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution|
M Kovac, C Navas, S Horswell, M Salm, C Bardella, A Rowan, M Stares, ...
Nature communications 6, 6336, 2015
|The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma|
JSP Yuen, ME Cockman, M Sullivan, A Protheroe, GDH Turner, ...
Oncogene 26 (45), 6499, 2007
|Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma|
A Protheroe, JCW Edwards, A Simmons, K Maclennan, P Selby
Rheumatology 38 (11), 1150-1152, 1999
|Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive …|
KN Chi, A Protheroe, A Rodríguez-Antolín, G Facchini, H Suttman, ...
The Lancet Oncology, 2018
|A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours|
SP Blagden, LR Molife, A Seebaran, M Payne, AHM Reid, AS Protheroe, ...
British journal of cancer 98 (5), 894, 2008
|Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study|
P Mulders, R Hawkins, P Nathan, I de Jong, S Osanto, E Porfiri, ...
European Journal of Cancer 48 (4), 527-537, 2012
|Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia|
F Ponchel, RJ Verburg, SJ Bingham, AK Brown, J Moore, A Protheroe, ...
Arthritis Res Ther 7 (1), R80, 2004